{"ticker": {"uuid": "cdf0202f-e6be-45e8-bbcd-3bd230934532", "symbol": "PEN", "name": "Penumbra Inc", "exchange": "NYSE", "country": "US", "sector": "Healthcare", "industry": "Medical Devices"}, "articles": [{"title": "Analyst Report: Penumbra, Inc.", "summary": "", "url": "https://finance.yahoo.com/m/d9f89836-86d6-30c3-a319-42b2e83411c7/analyst-report%3A-penumbra%2C-inc..html", "source_name": "Morningstar Research", "published_at": "2026-07-17T14:51:17+00:00", "published_display": "17 Jul 2026 14:51", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Risk of Antitrust Challenges Remains Low for Boston's Acquisition of Penumbra", "summary": "Morningstar analyst Debbie S. Wang reiterated that the risk of antitrust challenges for Boston Scientific's planned acquisition of Penumbra remains low. The article highlights Penumbra's history of creating innovative endovascular devices for blood clots and aneurysms, positionin", "url": "https://www.morningstar.com/company-reports/1488247-risk-of-antitrust-challenges-remains-low-for-bostons-acquisition-of-penumbra", "source_name": "Morningstar", "published_at": "2026-07-17T15:10:50", "published_display": "17 Jul 2026 15:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 96, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Penumbra (PEN) Stock Forum and Discussion", "summary": "This article provides a forum and discussion board for Penumbra (PEN) stock. It allows investors to share insights and engage in discussions about the company's performance, news, and future outlook. The content is primarily user-generated, focusing on various aspects relevant to", "url": "https://www.moomoo.com/stock/PEN-US/community?global_content=%7B%22promote_id%22%3A13764,%22sub_promote_id%22%3A62%7D", "source_name": "Moomoo", "published_at": "2026-07-15T09:41:18", "published_display": "15 Jul 2026 09:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Reflecting On Medical Devices & Supplies - Specialty Stocks\u2019 Q1 Earnings: Integer Holdings (NYSE:ITGR)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqgFBVV95cUxNUFd1SUpRcWlCdEFjU1YzNTZkdjBfRkwyY2lBYjh1ZXZlZTlyVlpWSWx1bExvckFrNHNhUEdVTGNFWUxaMkVDZUV2c2hPS1h2YVhNSHNsVzFYNUFrNHBnRVM1STRsa2Zmb0VXeEQ4UFRGNDBOWXZfWVU5VFUyQ3JZZm9KamZMWXVDSEtNMWwyVktpaEZfRjVNU1BYaWJ3NnpNUmRyMEpsSzBXdw?oc=5", "source_name": "Market source", "published_at": "2026-07-14T18:07:11+00:00", "published_display": "14 Jul 2026 18:07", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "(PEN) Volatility Zones as Tactical Triggers", "summary": "This article analyzes Penumbra Inc. (NYSE: PEN) using AI models, identifying neutral near and mid-term readings but a positive long-term bias. It outlines distinct institutional trading strategies, including position, momentum breakout, and risk hedging, tailored to different ris", "url": "https://news.stocktradersdaily.com/news_release/150/PEN_Volatility_Zones_as_Tactical_Triggers_071326094202_1783950122.html", "source_name": "Stock Traders Daily", "published_at": "2026-07-13T10:10:12", "published_display": "13 Jul 2026 10:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to EBITDA forward of Penumbra, Inc. \u2013 NYSE:PEN", "summary": "This article provides the enterprise value to EBITDA forward for Penumbra, Inc. (NYSE: PEN). It indicates that the market was closed and no trades occurred at the time of publication, with data provided by ICE Data Services and FactSet.", "url": "https://www.tradingview.com/symbols/NYSE-PEN/financials-statistics-and-ratios/enterprise-value-ebitda-fwd/", "source_name": "TradingView", "published_at": "2026-07-11T06:10:17", "published_display": "11 Jul 2026 06:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Penumbra starts trial of clot removal device in stroke subgroup", "summary": "Penumbra has initiated a clinical trial to evaluate its RED reperfusion catheter portfolio for mechanical thrombectomy in patients with M2 occlusions, a subset of acute ischemic stroke. This study aims to inform treatment selection and potentially broaden the adoption of mechanic", "url": "https://www.medtechdive.com/news/penumbra-starts-trial-of-clot-removal-device-in-stroke-subgroup/824664/", "source_name": "MedTech Dive", "published_at": "2026-07-08T15:40:29", "published_display": "08 Jul 2026 15:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "How Penumbra\u2019s FORWARD Stroke Trial Could Shape THUNDERBOLT Catheter Adoption for PEN Investors", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-07-08T04:51:59+00:00", "published_display": "08 Jul 2026 04:51", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "First Patient Enrolled in Penumbra's FORWARD Study Evaluating Mechanical Thrombectomy and Computer Assisted Vacuum Thrombectomy for Distal Acute Ischemic Stroke", "summary": "Penumbra, Inc. has initiated its FORWARD study, an international, multi-center study to evaluate the safety and efficacy of mechanical thrombectomy, including computer assisted vacuum thrombectomy (CAVT\u2122), for distal acute ischemic stroke. The study, which has enrolled its first ", "url": "https://www.barchart.com/story/news/3162843/first-patient-enrolled-in-penumbra-s-forward-study-evaluating-mechanical-thrombectomy-and-computer-assisted-vacuum-thrombectomy-for-distal-acute-ischemic-stroke", "source_name": "Barchart.com", "published_at": "2026-07-07T20:17:43", "published_display": "07 Jul 2026 20:17", "sentiment": "positive", "sentiment_pct": 72, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Penumbra enrolls first patient in distal acute stroke thrombectomy study", "summary": "Penumbra has initiated the FORWARD study to collect safety and efficacy data on its mechanical thrombectomy technology for distal acute ischemic stroke with M2 occlusions. The real-world, prospective, multi-center study will enroll up to 250 participants and evaluate Penumbra's R", "url": "https://www.massdevice.com/penumbra-first-patient-forward-stroke-study/", "source_name": "MassDevice", "published_at": "2026-07-07T18:35:45", "published_display": "07 Jul 2026 18:35", "sentiment": "positive", "sentiment_pct": 75, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Penumbra initiates study on stroke treatment for distal occlusions", "summary": "Penumbra Inc. has launched its FORWARD study, an international multi-center study investigating mechanical thrombectomy for acute ischemic stroke with distal occlusions. The study aims to collect safety and efficacy data on this treatment, evaluating Penumbra's RED reperfusion ca", "url": "https://www.investing.com/news/company-news/penumbra-initiates-study-on-stroke-treatment-for-distal-occlusions-93CH-4779443", "source_name": "Investing.com", "published_at": "2026-07-07T15:40:28", "published_display": "07 Jul 2026 15:40", "sentiment": "positive", "sentiment_pct": 70, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Penumbra enrolls first patient in stroke study for M2 occlusions", "summary": "", "url": "https://news.google.com/rss/articles/CBMitgFBVV95cUxQbzd6QWlVZFJKczVTbmltZ3lOUlg2dFRUWE15U3dfQ3NpaVFpZE9FSHVtN194cUg0NFU0ZURuaTJxZm9mUHhtTUo2RWs5NExoa0l0cXpKTjduWDUwaUpXNUp1YWFrVkhHbkhicndId0VqeVF0NXZjT282d2JnZVFsUXNlRjNKUkNWSHZXa2wxR2FCdzQ4d0VpRldWNnRPMG50MVpkYTFTZjdFLUdyczdDWHM2cnVoQQ?oc=5", "source_name": "Stock Titan", "published_at": "2026-07-07T07:00:00+00:00", "published_display": "07 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Penumbra, Inc. (PEN) Stock Analysis: A Healthcare Innovator with a 14.40% Potential Upside", "summary": "Penumbra, Inc. (NYSE: PEN) is a medical device company with a market cap of $12.53 billion, specializing in thrombectomy and embolization procedures. Analysts see a 14.40% potential upside with an average target price of $364.43, supported by strong revenue growth (15.60%) and a ", "url": "https://www.directorstalkinterviews.com/penumbra-inc-pen-stock-analysis-a-healthcare-innovator-with-a-14-40-potential-upside/4121255564", "source_name": "DirectorsTalk Interviews", "published_at": "2026-07-06T09:10:26", "published_display": "06 Jul 2026 09:10", "sentiment": "positive", "sentiment_pct": 86, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to earnings forward of Penumbra, Inc. \u2013 DUS:0P8", "summary": "This article provides financial data for Penumbra, Inc. (DUS:0P8) on the Dusseldorf Stock Exchange, specifically focusing on its forward Price to Earnings ratio. It presents an overview of the company's financials without detailed numbers, noting the market was closed at the time", "url": "https://www.tradingview.com/symbols/DUS-0P8/financials-statistics-and-ratios/price-earnings-fwd/", "source_name": "TradingView", "published_at": "2026-07-04T06:10:28", "published_display": "04 Jul 2026 06:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "PEN - Penumbra Inc Volatility & Greeks", "summary": "This article provides a detailed financial overview of Penumbra Inc (PEN), including its latest stock performance, key financial metrics, volatility data, and analyst recommendations. It covers various fundamental and technical indicators, insider and institutional ownership, and", "url": "https://finviz.com/stock?t=PEN&ty=ocv&ta=1&p=d&ov=list_strike&s=340", "source_name": "Finviz", "published_at": "2026-07-03T23:09:29", "published_display": "03 Jul 2026 23:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Penumbra Receives CE Mark for Reperfusion Catheters", "summary": "Penumbra Inc. has received the CE Mark for its Red 72 Silver Label and Red 72 Silver Label with SENDit Technology reperfusion catheters, designed for acute ischemic stroke. These devices offer significant engineering updates for enhanced trackability and ease of navigation, build", "url": "https://www.dicardiology.com/content/penumbra-receives-ce-mark-reperfusion-catheters", "source_name": "www.dicardiology.com", "published_at": "2026-07-02T17:39:06", "published_display": "02 Jul 2026 17:39", "sentiment": "positive", "sentiment_pct": 74, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Penumbra secures European CE mark for Red 72 Silver Label technologies", "summary": "Penumbra has received CE mark approval for its Red 72 Silver Label and Red 72 Silver Label with Sendit technology products in Europe. These reperfusion catheters, already available in the USA, offer significant updates for treating large vessel occlusion in acute ischemic stroke ", "url": "https://neuronewsinternational.com/penumbra-secures-european-ce-mark-for-red-72-silver-label-technologies/", "source_name": "NeuroNews International", "published_at": "2026-07-01T13:41:14", "published_display": "01 Jul 2026 13:41", "sentiment": "positive", "sentiment_pct": 74, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Penumbra, Inc. Unsponsored Brazilian Depositary Receipt Repr 0.033333 Sh", "summary": "This page provides an overview of financial actuals and estimates for Penumbra, Inc. (BMFBOVESPA:P2NB34), specifically for its Unsponsored Brazilian Depositary Receipt. Users can explore reported financial data and analyst estimates across income statements, balance sheets, cash ", "url": "https://www.tradingview.com/symbols/BMFBOVESPA-P2NB34/forecast-actuals-and-estimates/", "source_name": "TradingView", "published_at": "2026-06-28T02:39:45", "published_display": "28 Jun 2026 02:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "PEN Forecast \u2014 Price Target \u2014 Prediction for 2027", "summary": "This article provides a forecast for Penumbra, Inc. (PEN) stock, including analyst price targets, earnings estimates, and revenue projections. Analysts have provided 1-year price targets for PEN, with a maximum estimate of 6,593.79 MXN and a minimum estimate of 5,906.21 MXN. The ", "url": "https://www.tradingview.com/symbols/BIVA-PEN/forecast-price-target/", "source_name": "TradingView", "published_at": "2026-06-27T08:39:57", "published_display": "27 Jun 2026 08:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to sales forward of Penumbra, Inc. \u2013 HAM:0P8", "summary": "This page from TradingView focuses on the \"Price to sales forward\" financial metric for Penumbra, Inc. (HAM:0P8) on the Hamburg Stock Exchange. Although specific financial figures are not detailed, the page indicates that it provides human-made data and is part of TradingView's c", "url": "https://www.tradingview.com/symbols/HAM-0P8/financials-statistics-and-ratios/price-sales-fwd/", "source_name": "TradingView", "published_at": "2026-06-26T02:39:30", "published_display": "26 Jun 2026 02:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to earnings forward of Penumbra, Inc. \u2013 HAM:0P8", "summary": "This article provides financial information for Penumbra, Inc. (HAM:0P8) on the Hamburg Stock Exchange, specifically focusing on its Price to Earnings Forward. The content presents an overview of the company's financials and includes metadata from TradingView.", "url": "https://www.tradingview.com/symbols/HAM-0P8/financials-statistics-and-ratios/price-earnings-fwd/", "source_name": "TradingView", "published_at": "2026-06-25T16:41:14", "published_display": "25 Jun 2026 16:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to sales forward of Penumbra, Inc. \u2013 NYSE:PEN", "summary": "This article focuses on the \"Price to sales forward\" metric for Penumbra, Inc. (NYSE: PEN). It presents the company's financial data as provided by TradingView, detailing its market information and stock exchange listing. The content mainly consists of navigational links and copy", "url": "https://www.tradingview.com/symbols/NYSE-PEN/financials-statistics-and-ratios/price-sales-fwd/", "source_name": "TradingView", "published_at": "2026-06-25T09:41:43", "published_display": "25 Jun 2026 09:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Penumbra, Inc. 8-K SEC Filing: Key Details, Business Address, NYSE Listing & Shareholder Vote Results", "summary": "Penumbra, Inc. held its 2026 Annual Meeting of Stockholders on June 18, 2026, where shareholders voted on the election of directors, ratification of the independent auditor, and an advisory vote on executive compensation. All proposals passed by significant margins, indicating st", "url": "https://www.minichart.com.sg/2026/06/23/penumbra-inc-8-k-sec-filing-key-details-business-address-nyse-listing-shareholder-vote-results/", "source_name": "Minichart", "published_at": "2026-06-23T04:10:35", "published_display": "23 Jun 2026 04:10", "sentiment": "positive", "sentiment_pct": 67, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Penumbra: Portfolio Expands With Approval To Treat Stroke; Acquisition by Boston on Track", "summary": "Penumbra recently received US Food and Drug Administration approval and the CE Mark for its Thunderbolt computer-assisted vacuum aspiration system for ischemic stroke, expanding its portfolio. Concurrently, Boston Scientific is in the process of acquiring Penumbra. This developme", "url": "https://www.morningstar.com/company-reports/1485716-penumbra-portfolio-expands-with-approval-to-treat-stroke-acquisition-by-boston-on-track", "source_name": "Morningstar", "published_at": "2026-06-23T01:10:17", "published_display": "23 Jun 2026 01:10", "sentiment": "positive", "sentiment_pct": 71, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Penumbra (PEN) Canaccord Genuity 44th Annual Growth Conference & Private Company Showcase 2024 summary", "summary": "Penumbra presented at the Canaccord Genuity 44th Annual Growth Conference, focusing on its thrombectomy and embolization/access business units. The company highlighted its CAVT technology, including Lightning Flash 2.0 and Lightning Bolt 7, and the upcoming Thunderbolt for stroke", "url": "https://quartr.com/events/penumbra-inc-pen-canaccord-genuity-44th-annual-growth-conference-private-company-showcase-2_ojYAwNsB", "source_name": "Quartr", "published_at": "2026-06-23T01:10:16", "published_display": "23 Jun 2026 01:10", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Penumbra shareholders elect directors and approve executive pay at annual meeting", "summary": "Penumbra Inc. shareholders met to elect three Class II directors to serve until the 2027 annual meeting, ratify PricewaterhouseCoopers LLP as the independent public accounting firm, and approve executive compensation. The medical device company also recently received CE Mark appr", "url": "https://www.investing.com/news/sec-filings/penumbra-shareholders-elect-directors-and-approve-executive-pay-at-annual-meeting-93CH-4754463", "source_name": "Investing.com", "published_at": "2026-06-23T00:26:46", "published_display": "23 Jun 2026 00:26", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Form 8K Penumbra Inc For: 22 June By Investing.com", "summary": "This article announces that Penumbra Inc. filed a Form 8K for June 22. The article is very brief, serving mainly as a headline with no additional details about the filing's content. It also includes stock market data and other news.", "url": "https://ca.investing.com/news/stock-market-news/form-8k-penumbra-inc-for-22-june-93CH-4701732", "source_name": "Investing.com Canada", "published_at": "2026-06-23T00:00:46", "published_display": "23 Jun 2026 00:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Penumbra Expands Portfolio With Approval To Treat Stroke; Acquisition by Boston on Track", "summary": "Penumbra, a company specializing in endovascular systems for blood clots and aneurysms, has received approval to treat stroke. This development comes as the company is on track to be acquired by Boston Scientific by the end of 2026. Penumbra has built a growing presence in the th", "url": "https://www.morningstar.com/company-reports/1485718-penumbra-expands-portfolio-with-approval-to-treat-stroke-acquisition-by-boston-on-track", "source_name": "Morningstar", "published_at": "2026-06-22T18:40:46", "published_display": "22 Jun 2026 18:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "(PEN) Price Dynamics and Execution-Aware Positioning", "summary": "This article provides an AI-driven analysis for Penumbra Inc. (NYSE: PEN), indicating a neutral near and mid-term outlook with a moderating long-term positive bias and elevated downside risk. It details various trading strategies\u2014position, momentum breakout, and risk hedging\u2014alon", "url": "https://news.stocktradersdaily.com/news_release/8/PEN_Price_Dynamics_and_Execution-Aware_Positioning_062126072202_1782040922.html", "source_name": "Stock Traders Daily", "published_at": "2026-06-21T07:10:10", "published_display": "21 Jun 2026 07:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Penumbra (PEN) Stock Could Be 12.7% Undervalued On STORM PE Trial Hopes", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-06-19T07:00:00+00:00", "published_display": "19 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Penumbra Receives CE Nod for THUNDERBOLT: Stock to Gain?", "summary": "Penumbra recently received CE Mark approval in Europe for its THUNDERBOLT technology, a computer-assisted vacuum thrombectomy (CAVT) device for acute ischemic stroke, following FDA approval in the U.S. This expansion is expected to boost Penumbra's international revenues, which a", "url": "https://www.tradingview.com/news/zacks:baa6ebfdf094b:0-penumbra-receives-ce-nod-for-thunderbolt-stock-to-gain/", "source_name": "TradingView", "published_at": "2026-06-18T17:09:54", "published_display": "18 Jun 2026 17:09", "sentiment": "positive", "sentiment_pct": 67, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Penumbra wins CE mark for Thunderbolt clot removal tech", "summary": "Penumbra has secured a CE mark for its Thunderbolt computer-assisted vacuum thrombectomy device, allowing its launch in Europe for stroke patients. This European certification follows FDA clearance and positions Penumbra for global expansion, which could be significantly bolstere", "url": "https://www.medtechdive.com/news/penumbra-bags-ce-mark-for-clot-removal-technology/823239/", "source_name": "MedTech Dive", "published_at": "2026-06-18T15:09:55", "published_display": "18 Jun 2026 15:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Penumbra Inc (PEN) Valuation: PE, PB & Fair Value Analysis", "summary": "This article provides a valuation analysis of Penumbra Inc (PEN), noting its current valuation score of 7.10, which ranks 176 out of 204 in its industry. The company's current P/E ratio is 72.21, significantly below its recent high but above its recent low. The article indicates ", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-pen/company-valuation", "source_name": "TradingKey", "published_at": "2026-06-18T05:17:37", "published_display": "18 Jun 2026 05:17", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Penumbra (PEN) Proxy filing Summary", "summary": "", "url": "https://news.google.com/rss/articles/CBMickFVX3lxTE8yOHJYZDgxeXAxYWFpNGZPX0JPT1d1UjV4RW1JSXAyR3k5Tnc1NUZLMVVLdXd1QTV2MXpJam1iQWtmYjBfWXlwZFNhRFdlUnlfbnhaRnBvZmIyT180NDBmaExIYWROQUd5aHZxVWM3cHZmQQ?oc=5", "source_name": "Quartr", "published_at": "2026-06-17T23:01:11+00:00", "published_display": "17 Jun 2026 23:01", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Penumbra\u2019s Thunderbolt approval poised\u00a0to accelerate neuro thrombectomy innovation", "summary": "", "url": "https://finance.yahoo.com/m/cf411648-b137-379e-b044-28ad560b14df/penumbra%E2%80%99s-thunderbolt.html", "source_name": "Medical Device Network", "published_at": "2026-06-16T16:27:49+00:00", "published_display": "16 Jun 2026 16:27", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Medical Devices & Supplies - Cardiology, Neurology, Vascular Stocks Q1 Earnings: ICU Medical (NASDAQ:ICUI) Firing on All Cylinders", "summary": "", "url": "https://news.google.com/rss/articles/CBMikAJBVV95cUxQLWl0NWl5MFJhUXFSN0pzSW1sVzJVb21XVml0X0doQnd5eDVUQmVqeFZWSmNmdlZaV2pfbFk3UEl3RXlqZ05pckozR0dnNHNEUlpTa2FPYWc1Z3Q0Y2tXYTljZUlQRkVZNzY2Sl9yRksyUDJkNVQzSTBuLW9uMnI5bzBfTTJGdDUzd25DN3dDSmhwWnpGVXZRVVM2Uy1zMnp4STZ1RGdZZkRpZ21Pb2xtWjRSTk1kc2JrT28wTG81NDV1M2tWaVdrOXBQdVZSTExiTVEzMXpqRnJWWi0xcEdMYVFILXZXbXZVZl9GRm12aTl5OGk4X1dSVjVyU2FIVFpubk1YNm5fQll0MVZqRTZpTA?oc=5", "source_name": "StockStory", "published_at": "2026-06-15T07:00:00+00:00", "published_display": "15 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Why Is Penumbra (PEN) Down 1.2% Since Last Earnings Report?", "summary": "", "url": "https://news.google.com/rss/articles/CBMikgFBVV95cUxQSWFfejhmNk9xYTBZZHhMVGpROUlUUzZsTTI1N3lkUG0wa2dNbjNHZE5JX1hSa2FiTUJVZjZQeWJQd3hUUHdicS1lb05pUEpscElQNVRGQXNaVE50Y1ZjUFRxRlk3Tm0ySkVwSGJ5TEpmYXVTSk4yUk1qT0YtbDJXRU9vdkZOYXRnOGJLX29vbUk5Zw?oc=5", "source_name": "Market source", "published_at": "2026-06-05T07:00:00+00:00", "published_display": "05 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Q1 Earnings Review: Medical Devices & Supplies - Diversified Stocks Led by Baxter (NYSE:BAX)", "summary": "", "url": "https://news.google.com/rss/articles/CBMipgFBVV95cUxNYjhBT3BjMWFVU1FFUUFub0d6QUVEUTdwWFVMRG5fN2dHSnIxTXQwMWU1aElKaEV1a2dYLTFHMlBzMVFTZEtaX0xRRDFhZDl1WFdDYWF2RDZxOG9SRUtycmZacTRzM2FaaEU3OS1GZ2taLWtSMjZ4enhVNHRvdzJsanp4cEhNcGI1dllTOUplWUUtNjRlRm85MlFEVWxSYUV2d243QVd3?oc=5", "source_name": "Market source", "published_at": "2026-05-21T07:00:00+00:00", "published_display": "21 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Assessing Penumbra (PEN) Valuation As Growth Expectations Meet A Premium P/E Multiple", "summary": "", "url": "https://news.google.com/rss/articles/CBMipwFBVV95cUxNTDVEZWw4a3Vqb094eVBfcTBrOG1jcTZmbmVma0N4TEJibi10N3d0MWNYM1NhVVBfbVZveDVBM20wTy1mT1BhVW11Z2JxRjBUUmJDYWRQRFpwOTNPNFQ4NGpjbXhEYXNIM3Zpd1FPcXQ1aDNjWVVfWXhrMWc4WEs3NDYxanhUNU96eEcyY291anhrYUtORUYzbHBaWWdvOXl2RWZXcE93aw?oc=5", "source_name": "Market source", "published_at": "2026-05-07T07:00:00+00:00", "published_display": "07 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Penumbra (NYSE: PEN) shareholders approve Merger Proposal; closing conditions remain", "summary": "", "url": "https://news.google.com/rss/articles/CBMisgFBVV95cUxNNkI2c0pmckFQaVF1MUhKVUhRTG5PaF9vMDY0c0VEZ0FTX1BmQmNid1U2dnRvcnViUGZTSmVEakRBeUVlNmFxZEFjNkhWT2JxcXpnRkZyOHpuUHVYak1GdVhJVXQ0Q0QtNUtzWk53M2VIMEVseV9uQ1MwamloWUY5MGxFbUVrTnhoTG9Za2pwbEtkUWZRRzJfN1JKWVNtSHEtN1ZVQ05kb3RVUzJaclMtRkxB?oc=5", "source_name": "Stock Titan", "published_at": "2026-05-07T07:00:00+00:00", "published_display": "07 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Penumbra posts $32.6M profit as Boston Scientific deal halts outlook", "summary": "", "url": "https://news.google.com/rss/articles/CBMipgFBVV95cUxQQllMRGoyOGRaYW9rbUF5d0FZSDV4eU1DNk5kbWwxcDVFekdRMHZqV1pDVFBQTTl1R1Y0SUJyU2RKbDBGVnZEVFJvYk1EVlRjVWpMd2p6QzdiVEJDWk5LblB4eEQ0TVdVaW5wUjctMnlIN1Y0aTVzdG1KekxCZ3dnbHEzNGVPRGcyOTRDcXBjdkZEV1psa2I2OENLd2lvamNmM3lJMTNR?oc=5", "source_name": "Stock Titan", "published_at": "2026-05-06T07:00:00+00:00", "published_display": "06 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Penumbra (NYSE: PEN) outlines 2026 meeting and $14.5B Boston Scientific sale", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxQcWxtM0hQdl9xXzBCWDJoWnZXYUtuNG92ZjM2cDZHS2NHOE1LUncxU1FiS2praXVrMHVGZFNqRG0tdWlKSjFzcDJxX1phY1pNTGlsRDBSWm5NSFdIMVdvMlJYNjgtdS1jSFlmcEhlYkx3X0dzbVVKbC1ydXp5d2lySTNzNkRrZEx4N0ppSHFLbnhmTkdmUHUxNXRfQUtuRUpMWUFLaGRwdU9QaFJr?oc=5", "source_name": "Stock Titan", "published_at": "2026-04-29T07:00:00+00:00", "published_display": "29 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Medical Devices & Supplies - Specialty Q4 Earnings: Globus Medical (NYSE:GMED) is the Best in the Biz", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqgFBVV95cUxNcDFMNmtOVk5PVFM1YzMyVWhyS3dwY0dMVE5BUng5U1JoOFRQMXNFRGxTMmlBRUV0bENRSWFXTDFZOXBQQkNZT0FOWDdISjRCcU9pRV9aNHBwUVBuZkVEV3g1dklVY19KOE9iWUNpNUtMS2NuOEcxMlQtNU8ydURybEdkNVoxZThWLTBIeVhid2NjQ0FWWTUzb2dxcmlMQThFQmZ4bldzRjcwUQ?oc=5", "source_name": "Market source", "published_at": "2026-04-27T07:00:00+00:00", "published_display": "27 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "A Look Back at Medical Devices & Supplies - Imaging, Diagnostics Stocks\u2019 Q4 Earnings: Hologic (NASDAQ:HOLX) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMipgFBVV95cUxOdkl6Ym5HSGVhZUw3TzNlNVFPSjdDQk5NMTVSRW1xVnh3RE5RNU9veVR0TDEtcVdxV3BYelI0bWxCYXgwWmhZQ3ZONUVRdlhjX0ZiMklRVDJQRXN0LXcyVWVnb0E2WTdiRERtZk1pNGpmVHhWbHl5eHJuNnBtTDVPMUluTmRsQUVqYjNlSl8zR3djclh0X2ZIc1gzTlhPanR6ZTJ6R1FB?oc=5", "source_name": "Market source", "published_at": "2026-04-07T07:00:00+00:00", "published_display": "07 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Q4 Earnings Highlights: Artivion (NYSE:AORT) Vs The Rest Of The Medical Devices & Supplies - Cardiology, Neurology, Vascular Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqAFBVV95cUxPaTgxS3dlMlZ5dDZ3dFlGdG9yRWFubkVqMk9yOTN6OEtyemljTWJGYUcxb2pmd2FTNTFKMlhIVGxrdlJsOG5iY1VQaXE4ZmYycTVpRkE0aEJ3QlB5bC10ZXN2dTFYNy0wRWdrNURVUlo5dEMzQklxQ0kwQTRkOXE0UDdTMkRGRWxoQ1ZQeG4tOXNONlR2SkxfZW5ST1B6N3BBeFZZQ3N1UFE?oc=5", "source_name": "Market source", "published_at": "2026-04-02T07:00:00+00:00", "published_display": "02 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Q4 Earnings Highlights: CooperCompanies (NASDAQ:COO) Vs The Rest Of The Medical Devices & Supplies - Diversified Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMitAFBVV95cUxOellVLTAtRXF1dTFacmVLUmptUVpDSkxGX0MtY2hCY2l3ajU4M25SMG95OHdlc1RHN1dmaHZZMF9uQ0o3R1FBa0NzQUtZMjIzMjU1bmttbGZsZUplQkd5Vmd2NEJoQ0NnbVhmVXppdWhiQkdpcGpQVFJVSHRBXy1pbnFJbXI0R2w3MmlvMEdCY2dGYVE4cWY2MENmeEp1ME9mZEFqSDVtdThTMk9kbUhIdXMtR0k?oc=5", "source_name": "Market source", "published_at": "2026-03-25T07:00:00+00:00", "published_display": "25 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Unpacking Q4 Earnings: Integer Holdings (NYSE:ITGR) In The Context Of Other Medical Devices & Supplies - Specialty Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMijAFBVV95cUxQZXhDWktWZlhhSHlxNVZrNWllaDhhWlNXZmhKYlQ4ODRJMHozNTR2TVVKSWVrQV94bzNNU0hfVW5qODRlWW01anFmTG5SYmZoUlJpU09UbkpSemxVbHRGb1F1MGVvZFdqSEVBcUZ5Ti1ZVHlzY3pZYTdCS21RcDJPTnppdWRKVlZjd2ZUeA?oc=5", "source_name": "Market source", "published_at": "2026-03-17T07:00:00+00:00", "published_display": "17 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Q4 Earnings Highs And Lows: Abbott Laboratories (NYSE:ABT) Vs The Rest Of The Medical Devices & Supplies - Diversified Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMigAFBVV95cUxPeVpVN2I3X3lJNXd3TXJmRWV4X0RvRDdYR3l5a1k1SjMxUlhsWHdrUUNuZ1JIaUg4czdhZlA2VDVIallROFFuNmZXcnNzS1d3Vm0wS0tLMmlFVWdkUThsRDZYdTdZV3k3WkRjaUZSMUQ3dkRKYm5ZOVBjMVVBdTRjYQ?oc=5", "source_name": "Market source", "published_at": "2026-03-12T07:00:00+00:00", "published_display": "12 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Unpacking Q4 Earnings: Enovis (NYSE:ENOV) In The Context Of Other Medical Devices & Supplies - Specialty Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMihgFBVV95cUxNMzBPcXU1cnZKekZnaGlNVk05ZWFTWThNOS0tTlpvQjdaLVZIWlVXUk50NnVoQ0pPWWJpZUpWcVJyVDJMd2RJREVDbEEzTlU5UGhBbWtxWVEyVkdaMTVuNXZpaWFMNTZUQ2d0OW9Rc29kalJRY21naWlHZDBLS3RuZV9wdTdIUQ?oc=5", "source_name": "Market source", "published_at": "2026-03-10T07:00:00+00:00", "published_display": "10 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Penumbra Sale To Boston Scientific Puts Focus On Deal Terms And Future", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-03-04T08:00:00+00:00", "published_display": "04 Mar 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why is Boston Scientific Acquiring Penumbra", "summary": "", "url": "https://news.google.com/rss/articles/CBMihAFBVV95cUxNYW1NbVZkcGZsQ0g1VV9jakNiN1lxMnNMdWNPLXpjZm9VTDFwdWN4cnNPanh5NmFvQnNxQmdWbFRSRXotcXRYc3VmSEYwcWtLM0NZdjJsNDUyYWRzWVY0MzRNemhsMzNpOWF3blBWZGFUcmc0X1drWEZnQnEyT3NwcldJaEk?oc=5", "source_name": "Kavout | AI", "published_at": "2026-02-27T21:38:00+00:00", "published_display": "27 Feb 2026 21:38", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Penumbra, Inc. Reports Fourth Quarter and Full Year 2025 Financial Results", "summary": "", "url": "https://news.google.com/rss/articles/CBMixwFBVV95cUxQLXl2Q1p2cGlfd1YtQUlva2hlZ1J1eWs4V1JkLXVoSG95clZHdGJDOFBzU00xRzhHLXpuS2R4Z2RLci10UHhrbXNXcmRmdzA4WFFHWE95QUFqeTBHTGJVMXhDUVFjNVNwZzM3Qk8zUkJoaVBOcnNCaENBOWRfTm1vM0o3c0tmQ2QxRWx2OXBfTUlzNmpaMTg0bkpaYWU0Mm9tY19WQk5wVFlVMDFTZ0s2WWxxT1RqRG1Ib191T3V0c25zN1QteVhJ?oc=5", "source_name": "PR Newswire", "published_at": "2026-02-25T08:00:00+00:00", "published_display": "25 Feb 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Penumbra Inc SEC 10-K Report", "summary": "", "url": "https://news.google.com/rss/articles/CBMilAFBVV95cUxPeVg5SkpYUnRWZEk2QjRwaFowc2lJZHNlYUVHakFkeEtkRTlSRnhOSk5LeVl2RE9tX20tTTRjS0VXbGgxd3dnbnktcDc1M1dxWXdtU1JJZkFybXJuN1lFMUw2VXVlVWNfd0tCcXoxUFpKT2lIT0xhbk9jNlNZakFVVTdOb00xcTFpMFZBMVpaNmZicy0z?oc=5", "source_name": "TradingView", "published_at": "2026-02-25T08:00:00+00:00", "published_display": "25 Feb 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Penumbra (PEN) Climbs to All-Time High on $14.5-Billion Merger", "summary": "", "url": "https://news.google.com/rss/articles/CBMigAFBVV95cUxPdkhyYXBXZ05DQ2hQRUcwejdKS1pUS1ptSWY4aVc5WnpXNk5JRUc1aTF3VXdTRmI1RHpLQ0JPZmVHS3lUN2pZX19rMVozS1E0WkgtbXdDT2tWb1RsQ2VCSmdKbl85eTVvRUs2czNsY0JOckREN2FQN0UtSXlBMlFRZw?oc=5", "source_name": "Market source", "published_at": "2026-01-16T08:00:00+00:00", "published_display": "16 Jan 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Boston Scientific announces agreement to acquire Penumbra", "summary": "", "url": "https://news.google.com/rss/articles/CBMiiAFBVV95cUxNUWg3ck5YN2pOYkpFcjZMWjc4VXFTek9od2RFTThIV3UtZHpNTllCTkYzckxWQWVhMzVBQ2xXSXRyVjZRZnlaLUtyZjV4MTlCRzhfRVI2V1R2LWx2NXJ1aVQyLUhId2dpR3AtaldlY3FoRXk2eko4djVsOGV6VGIwLW9ndW9uX2ky?oc=5", "source_name": "Venous News", "published_at": "2026-01-15T08:00:00+00:00", "published_display": "15 Jan 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Boston Scientific set to re-enter neurovascular market with Penumbra acquisition", "summary": "", "url": "https://news.google.com/rss/articles/CBMitwFBVV95cUxPcHBJTzVtWGkxME5mWkVhN2RwYzR5b25vdmZuTnRIaUtNR0daT0tKZmtYSmRJRmZTaXlldjdUU3RxMmpEeWF2UVMwLUJnejgtLXltVUxacGJCRHlPQXlaNzRtR3lQVmpDbGpHbXk2MXdKanRycXdqN1U4cGtxY1R5U00wMUdxVC1FYl9YaGhEZmdETVlfTU5Ickt0eWxoZDFhS2drUXlmdUlPbmVZZVcyUm4wcDVvNms?oc=5", "source_name": "NeuroNews International", "published_at": "2026-01-15T08:00:00+00:00", "published_display": "15 Jan 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Boston Scientific Acquiring Penumbra Was The Logical Next Step (NYSE:BSX)", "summary": "", "url": "https://news.google.com/rss/articles/CBMioAFBVV95cUxNNVNSUFZtVTRrNXBSWGEyNTd6ZWxQUlZVdVRkM05iUzdLQVl0YzRvTmRlWGZ2SlM5d1Q5aXVvaHlrYzVWTWZ1MzBoSWtTR044OFlYMVhnN3NvVTBMWHpWWjk4UDBDRFplbG9FV2x4eHp5d0h0Z1FlejZLaG1VZUJHOXk1SVNuM3BHWXRQZ1FjQTI0VWh2OV9JRlRuN1RMNW1K?oc=5", "source_name": "Seeking Alpha", "published_at": "2026-01-15T08:00:00+00:00", "published_display": "15 Jan 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why Penumbra (PEN) Stock Is Trading Up Today", "summary": "", "url": "https://news.google.com/rss/articles/CBMiggFBVV95cUxPaENxeWxWWnFEN2taQ3VaSlR1TV9laHRJaWdoM1ZXSXN6cUFPQ29JUjdFZzg1TWdfcmtoSi16Yy1UbVNGUlVvODVWNGFRMmRvNkE1VERidjJrbnFtZXhWSWRUZ19UYnRaZ19RYlRpbVJZTW1LdVRUTHFCSnpXZGtvMC1R?oc=5", "source_name": "Market source", "published_at": "2026-01-15T08:00:00+00:00", "published_display": "15 Jan 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Do Penumbra's (NYSE:PEN) Earnings Warrant Your Attention?", "summary": "", "url": "https://news.google.com/rss/articles/CBMiugFBVV95cUxNMXpidTFEYWhFajN4YWdDOVV4MWZzMUNaelh2bHg3ZU5iV1JOQi0xeU54WmF4Zm9wYnlqSGZSUjNlZ3kwc0lzYkw2Z21nVHRuUTB2TGo2RlkwRlZzNVZhd0Njejd1ZXNmeW9sNkZnVmRxSGFOb2lmT2pIaXpkYm4zSFVxSXc3aE92Zk0wZXVYQTRTVlBBU1hDMlowcXJDTzZVZE5wR045OV9QMnZzaTV3RUNxSTlPSEMwWWfSAb8BQVVfeXFMTXk5TjRtY0NmVlcwZktmbEVtaUhscVpFVnZyMlBqYUJFck1yb2dKQktWQjFSS3dhZ2ZQMnBpRk5XNkVNZmI2ZW9jMHA5N2ZWNEhWQkpadEdkdWdvOEQzcXZ6cGQwU2hZTG5NYmZuTk1JR2xELXl0UWVXM2ZWaTdlNERCN1JXSmFtSnJqZmlvSTBodWVVY2Q2YUNWNjNMVEtVS2Y3V244X3o2ZTc1Tm8tN2NzSHdjQ3NrSnlkV21IME0?oc=5", "source_name": "simplywall.st", "published_at": "2026-01-11T08:00:00+00:00", "published_display": "11 Jan 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Penumbra, Inc. Reports Third Quarter 2025 Financial Results", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPMzRSZDhQa1Y5RllQdEg2SVdLdWN2ODYxTUI1aVpEUlhOSU9LR1FmWnQzUk1NeEc1M1MxeExTZ1dCTmxrYkdiWHFZOFBRejVtd2RTcHA3VjRralJlbnNNTzFtWERIMTNkMmlFUXhTSV9BdFYySDd3a09WemZtRklTcFdiQkRjYlBvZjdqSy1WUER4SmV5ck02V1VBaGJDNmxiemo0VFI1UksyLTZFdUVkWUFTbw?oc=5", "source_name": "PR Newswire", "published_at": "2025-11-05T08:00:00+00:00", "published_display": "05 Nov 2025 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}], "by_tier": {"direct": [{"title": "Analyst Report: Penumbra, Inc.", "summary": "", "url": "https://finance.yahoo.com/m/d9f89836-86d6-30c3-a319-42b2e83411c7/analyst-report%3A-penumbra%2C-inc..html", "source_name": "Morningstar Research", "published_at": "2026-07-17T14:51:17+00:00", "published_display": "17 Jul 2026 14:51", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Risk of Antitrust Challenges Remains Low for Boston's Acquisition of Penumbra", "summary": "Morningstar analyst Debbie S. Wang reiterated that the risk of antitrust challenges for Boston Scientific's planned acquisition of Penumbra remains low. The article highlights Penumbra's history of creating innovative endovascular devices for blood clots and aneurysms, positionin", "url": "https://www.morningstar.com/company-reports/1488247-risk-of-antitrust-challenges-remains-low-for-bostons-acquisition-of-penumbra", "source_name": "Morningstar", "published_at": "2026-07-17T15:10:50", "published_display": "17 Jul 2026 15:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 96, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Penumbra (PEN) Stock Forum and Discussion", "summary": "This article provides a forum and discussion board for Penumbra (PEN) stock. It allows investors to share insights and engage in discussions about the company's performance, news, and future outlook. The content is primarily user-generated, focusing on various aspects relevant to", "url": "https://www.moomoo.com/stock/PEN-US/community?global_content=%7B%22promote_id%22%3A13764,%22sub_promote_id%22%3A62%7D", "source_name": "Moomoo", "published_at": "2026-07-15T09:41:18", "published_display": "15 Jul 2026 09:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "(PEN) Volatility Zones as Tactical Triggers", "summary": "This article analyzes Penumbra Inc. (NYSE: PEN) using AI models, identifying neutral near and mid-term readings but a positive long-term bias. It outlines distinct institutional trading strategies, including position, momentum breakout, and risk hedging, tailored to different ris", "url": "https://news.stocktradersdaily.com/news_release/150/PEN_Volatility_Zones_as_Tactical_Triggers_071326094202_1783950122.html", "source_name": "Stock Traders Daily", "published_at": "2026-07-13T10:10:12", "published_display": "13 Jul 2026 10:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to EBITDA forward of Penumbra, Inc. \u2013 NYSE:PEN", "summary": "This article provides the enterprise value to EBITDA forward for Penumbra, Inc. (NYSE: PEN). It indicates that the market was closed and no trades occurred at the time of publication, with data provided by ICE Data Services and FactSet.", "url": "https://www.tradingview.com/symbols/NYSE-PEN/financials-statistics-and-ratios/enterprise-value-ebitda-fwd/", "source_name": "TradingView", "published_at": "2026-07-11T06:10:17", "published_display": "11 Jul 2026 06:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Penumbra starts trial of clot removal device in stroke subgroup", "summary": "Penumbra has initiated a clinical trial to evaluate its RED reperfusion catheter portfolio for mechanical thrombectomy in patients with M2 occlusions, a subset of acute ischemic stroke. This study aims to inform treatment selection and potentially broaden the adoption of mechanic", "url": "https://www.medtechdive.com/news/penumbra-starts-trial-of-clot-removal-device-in-stroke-subgroup/824664/", "source_name": "MedTech Dive", "published_at": "2026-07-08T15:40:29", "published_display": "08 Jul 2026 15:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "How Penumbra\u2019s FORWARD Stroke Trial Could Shape THUNDERBOLT Catheter Adoption for PEN Investors", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-07-08T04:51:59+00:00", "published_display": "08 Jul 2026 04:51", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "First Patient Enrolled in Penumbra's FORWARD Study Evaluating Mechanical Thrombectomy and Computer Assisted Vacuum Thrombectomy for Distal Acute Ischemic Stroke", "summary": "Penumbra, Inc. has initiated its FORWARD study, an international, multi-center study to evaluate the safety and efficacy of mechanical thrombectomy, including computer assisted vacuum thrombectomy (CAVT\u2122), for distal acute ischemic stroke. The study, which has enrolled its first ", "url": "https://www.barchart.com/story/news/3162843/first-patient-enrolled-in-penumbra-s-forward-study-evaluating-mechanical-thrombectomy-and-computer-assisted-vacuum-thrombectomy-for-distal-acute-ischemic-stroke", "source_name": "Barchart.com", "published_at": "2026-07-07T20:17:43", "published_display": "07 Jul 2026 20:17", "sentiment": "positive", "sentiment_pct": 72, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Penumbra enrolls first patient in distal acute stroke thrombectomy study", "summary": "Penumbra has initiated the FORWARD study to collect safety and efficacy data on its mechanical thrombectomy technology for distal acute ischemic stroke with M2 occlusions. The real-world, prospective, multi-center study will enroll up to 250 participants and evaluate Penumbra's R", "url": "https://www.massdevice.com/penumbra-first-patient-forward-stroke-study/", "source_name": "MassDevice", "published_at": "2026-07-07T18:35:45", "published_display": "07 Jul 2026 18:35", "sentiment": "positive", "sentiment_pct": 75, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Penumbra initiates study on stroke treatment for distal occlusions", "summary": "Penumbra Inc. has launched its FORWARD study, an international multi-center study investigating mechanical thrombectomy for acute ischemic stroke with distal occlusions. The study aims to collect safety and efficacy data on this treatment, evaluating Penumbra's RED reperfusion ca", "url": "https://www.investing.com/news/company-news/penumbra-initiates-study-on-stroke-treatment-for-distal-occlusions-93CH-4779443", "source_name": "Investing.com", "published_at": "2026-07-07T15:40:28", "published_display": "07 Jul 2026 15:40", "sentiment": "positive", "sentiment_pct": 70, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Penumbra enrolls first patient in stroke study for M2 occlusions", "summary": "", "url": "https://news.google.com/rss/articles/CBMitgFBVV95cUxQbzd6QWlVZFJKczVTbmltZ3lOUlg2dFRUWE15U3dfQ3NpaVFpZE9FSHVtN194cUg0NFU0ZURuaTJxZm9mUHhtTUo2RWs5NExoa0l0cXpKTjduWDUwaUpXNUp1YWFrVkhHbkhicndId0VqeVF0NXZjT282d2JnZVFsUXNlRjNKUkNWSHZXa2wxR2FCdzQ4d0VpRldWNnRPMG50MVpkYTFTZjdFLUdyczdDWHM2cnVoQQ?oc=5", "source_name": "Stock Titan", "published_at": "2026-07-07T07:00:00+00:00", "published_display": "07 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Penumbra, Inc. (PEN) Stock Analysis: A Healthcare Innovator with a 14.40% Potential Upside", "summary": "Penumbra, Inc. (NYSE: PEN) is a medical device company with a market cap of $12.53 billion, specializing in thrombectomy and embolization procedures. Analysts see a 14.40% potential upside with an average target price of $364.43, supported by strong revenue growth (15.60%) and a ", "url": "https://www.directorstalkinterviews.com/penumbra-inc-pen-stock-analysis-a-healthcare-innovator-with-a-14-40-potential-upside/4121255564", "source_name": "DirectorsTalk Interviews", "published_at": "2026-07-06T09:10:26", "published_display": "06 Jul 2026 09:10", "sentiment": "positive", "sentiment_pct": 86, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to earnings forward of Penumbra, Inc. \u2013 DUS:0P8", "summary": "This article provides financial data for Penumbra, Inc. (DUS:0P8) on the Dusseldorf Stock Exchange, specifically focusing on its forward Price to Earnings ratio. It presents an overview of the company's financials without detailed numbers, noting the market was closed at the time", "url": "https://www.tradingview.com/symbols/DUS-0P8/financials-statistics-and-ratios/price-earnings-fwd/", "source_name": "TradingView", "published_at": "2026-07-04T06:10:28", "published_display": "04 Jul 2026 06:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "PEN - Penumbra Inc Volatility & Greeks", "summary": "This article provides a detailed financial overview of Penumbra Inc (PEN), including its latest stock performance, key financial metrics, volatility data, and analyst recommendations. It covers various fundamental and technical indicators, insider and institutional ownership, and", "url": "https://finviz.com/stock?t=PEN&ty=ocv&ta=1&p=d&ov=list_strike&s=340", "source_name": "Finviz", "published_at": "2026-07-03T23:09:29", "published_display": "03 Jul 2026 23:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Penumbra Receives CE Mark for Reperfusion Catheters", "summary": "Penumbra Inc. has received the CE Mark for its Red 72 Silver Label and Red 72 Silver Label with SENDit Technology reperfusion catheters, designed for acute ischemic stroke. These devices offer significant engineering updates for enhanced trackability and ease of navigation, build", "url": "https://www.dicardiology.com/content/penumbra-receives-ce-mark-reperfusion-catheters", "source_name": "www.dicardiology.com", "published_at": "2026-07-02T17:39:06", "published_display": "02 Jul 2026 17:39", "sentiment": "positive", "sentiment_pct": 74, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Penumbra secures European CE mark for Red 72 Silver Label technologies", "summary": "Penumbra has received CE mark approval for its Red 72 Silver Label and Red 72 Silver Label with Sendit technology products in Europe. These reperfusion catheters, already available in the USA, offer significant updates for treating large vessel occlusion in acute ischemic stroke ", "url": "https://neuronewsinternational.com/penumbra-secures-european-ce-mark-for-red-72-silver-label-technologies/", "source_name": "NeuroNews International", "published_at": "2026-07-01T13:41:14", "published_display": "01 Jul 2026 13:41", "sentiment": "positive", "sentiment_pct": 74, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Penumbra, Inc. Unsponsored Brazilian Depositary Receipt Repr 0.033333 Sh", "summary": "This page provides an overview of financial actuals and estimates for Penumbra, Inc. (BMFBOVESPA:P2NB34), specifically for its Unsponsored Brazilian Depositary Receipt. Users can explore reported financial data and analyst estimates across income statements, balance sheets, cash ", "url": "https://www.tradingview.com/symbols/BMFBOVESPA-P2NB34/forecast-actuals-and-estimates/", "source_name": "TradingView", "published_at": "2026-06-28T02:39:45", "published_display": "28 Jun 2026 02:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "PEN Forecast \u2014 Price Target \u2014 Prediction for 2027", "summary": "This article provides a forecast for Penumbra, Inc. (PEN) stock, including analyst price targets, earnings estimates, and revenue projections. Analysts have provided 1-year price targets for PEN, with a maximum estimate of 6,593.79 MXN and a minimum estimate of 5,906.21 MXN. The ", "url": "https://www.tradingview.com/symbols/BIVA-PEN/forecast-price-target/", "source_name": "TradingView", "published_at": "2026-06-27T08:39:57", "published_display": "27 Jun 2026 08:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to sales forward of Penumbra, Inc. \u2013 HAM:0P8", "summary": "This page from TradingView focuses on the \"Price to sales forward\" financial metric for Penumbra, Inc. (HAM:0P8) on the Hamburg Stock Exchange. Although specific financial figures are not detailed, the page indicates that it provides human-made data and is part of TradingView's c", "url": "https://www.tradingview.com/symbols/HAM-0P8/financials-statistics-and-ratios/price-sales-fwd/", "source_name": "TradingView", "published_at": "2026-06-26T02:39:30", "published_display": "26 Jun 2026 02:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to earnings forward of Penumbra, Inc. \u2013 HAM:0P8", "summary": "This article provides financial information for Penumbra, Inc. (HAM:0P8) on the Hamburg Stock Exchange, specifically focusing on its Price to Earnings Forward. The content presents an overview of the company's financials and includes metadata from TradingView.", "url": "https://www.tradingview.com/symbols/HAM-0P8/financials-statistics-and-ratios/price-earnings-fwd/", "source_name": "TradingView", "published_at": "2026-06-25T16:41:14", "published_display": "25 Jun 2026 16:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to sales forward of Penumbra, Inc. \u2013 NYSE:PEN", "summary": "This article focuses on the \"Price to sales forward\" metric for Penumbra, Inc. (NYSE: PEN). It presents the company's financial data as provided by TradingView, detailing its market information and stock exchange listing. The content mainly consists of navigational links and copy", "url": "https://www.tradingview.com/symbols/NYSE-PEN/financials-statistics-and-ratios/price-sales-fwd/", "source_name": "TradingView", "published_at": "2026-06-25T09:41:43", "published_display": "25 Jun 2026 09:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Penumbra, Inc. 8-K SEC Filing: Key Details, Business Address, NYSE Listing & Shareholder Vote Results", "summary": "Penumbra, Inc. held its 2026 Annual Meeting of Stockholders on June 18, 2026, where shareholders voted on the election of directors, ratification of the independent auditor, and an advisory vote on executive compensation. All proposals passed by significant margins, indicating st", "url": "https://www.minichart.com.sg/2026/06/23/penumbra-inc-8-k-sec-filing-key-details-business-address-nyse-listing-shareholder-vote-results/", "source_name": "Minichart", "published_at": "2026-06-23T04:10:35", "published_display": "23 Jun 2026 04:10", "sentiment": "positive", "sentiment_pct": 67, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Penumbra: Portfolio Expands With Approval To Treat Stroke; Acquisition by Boston on Track", "summary": "Penumbra recently received US Food and Drug Administration approval and the CE Mark for its Thunderbolt computer-assisted vacuum aspiration system for ischemic stroke, expanding its portfolio. Concurrently, Boston Scientific is in the process of acquiring Penumbra. This developme", "url": "https://www.morningstar.com/company-reports/1485716-penumbra-portfolio-expands-with-approval-to-treat-stroke-acquisition-by-boston-on-track", "source_name": "Morningstar", "published_at": "2026-06-23T01:10:17", "published_display": "23 Jun 2026 01:10", "sentiment": "positive", "sentiment_pct": 71, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Penumbra (PEN) Canaccord Genuity 44th Annual Growth Conference & Private Company Showcase 2024 summary", "summary": "Penumbra presented at the Canaccord Genuity 44th Annual Growth Conference, focusing on its thrombectomy and embolization/access business units. The company highlighted its CAVT technology, including Lightning Flash 2.0 and Lightning Bolt 7, and the upcoming Thunderbolt for stroke", "url": "https://quartr.com/events/penumbra-inc-pen-canaccord-genuity-44th-annual-growth-conference-private-company-showcase-2_ojYAwNsB", "source_name": "Quartr", "published_at": "2026-06-23T01:10:16", "published_display": "23 Jun 2026 01:10", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Penumbra shareholders elect directors and approve executive pay at annual meeting", "summary": "Penumbra Inc. shareholders met to elect three Class II directors to serve until the 2027 annual meeting, ratify PricewaterhouseCoopers LLP as the independent public accounting firm, and approve executive compensation. The medical device company also recently received CE Mark appr", "url": "https://www.investing.com/news/sec-filings/penumbra-shareholders-elect-directors-and-approve-executive-pay-at-annual-meeting-93CH-4754463", "source_name": "Investing.com", "published_at": "2026-06-23T00:26:46", "published_display": "23 Jun 2026 00:26", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Form 8K Penumbra Inc For: 22 June By Investing.com", "summary": "This article announces that Penumbra Inc. filed a Form 8K for June 22. The article is very brief, serving mainly as a headline with no additional details about the filing's content. It also includes stock market data and other news.", "url": "https://ca.investing.com/news/stock-market-news/form-8k-penumbra-inc-for-22-june-93CH-4701732", "source_name": "Investing.com Canada", "published_at": "2026-06-23T00:00:46", "published_display": "23 Jun 2026 00:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Penumbra Expands Portfolio With Approval To Treat Stroke; Acquisition by Boston on Track", "summary": "Penumbra, a company specializing in endovascular systems for blood clots and aneurysms, has received approval to treat stroke. This development comes as the company is on track to be acquired by Boston Scientific by the end of 2026. Penumbra has built a growing presence in the th", "url": "https://www.morningstar.com/company-reports/1485718-penumbra-expands-portfolio-with-approval-to-treat-stroke-acquisition-by-boston-on-track", "source_name": "Morningstar", "published_at": "2026-06-22T18:40:46", "published_display": "22 Jun 2026 18:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "(PEN) Price Dynamics and Execution-Aware Positioning", "summary": "This article provides an AI-driven analysis for Penumbra Inc. (NYSE: PEN), indicating a neutral near and mid-term outlook with a moderating long-term positive bias and elevated downside risk. It details various trading strategies\u2014position, momentum breakout, and risk hedging\u2014alon", "url": "https://news.stocktradersdaily.com/news_release/8/PEN_Price_Dynamics_and_Execution-Aware_Positioning_062126072202_1782040922.html", "source_name": "Stock Traders Daily", "published_at": "2026-06-21T07:10:10", "published_display": "21 Jun 2026 07:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Penumbra (PEN) Stock Could Be 12.7% Undervalued On STORM PE Trial Hopes", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-06-19T07:00:00+00:00", "published_display": "19 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Penumbra Receives CE Nod for THUNDERBOLT: Stock to Gain?", "summary": "Penumbra recently received CE Mark approval in Europe for its THUNDERBOLT technology, a computer-assisted vacuum thrombectomy (CAVT) device for acute ischemic stroke, following FDA approval in the U.S. This expansion is expected to boost Penumbra's international revenues, which a", "url": "https://www.tradingview.com/news/zacks:baa6ebfdf094b:0-penumbra-receives-ce-nod-for-thunderbolt-stock-to-gain/", "source_name": "TradingView", "published_at": "2026-06-18T17:09:54", "published_display": "18 Jun 2026 17:09", "sentiment": "positive", "sentiment_pct": 67, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Penumbra wins CE mark for Thunderbolt clot removal tech", "summary": "Penumbra has secured a CE mark for its Thunderbolt computer-assisted vacuum thrombectomy device, allowing its launch in Europe for stroke patients. This European certification follows FDA clearance and positions Penumbra for global expansion, which could be significantly bolstere", "url": "https://www.medtechdive.com/news/penumbra-bags-ce-mark-for-clot-removal-technology/823239/", "source_name": "MedTech Dive", "published_at": "2026-06-18T15:09:55", "published_display": "18 Jun 2026 15:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Penumbra Inc (PEN) Valuation: PE, PB & Fair Value Analysis", "summary": "This article provides a valuation analysis of Penumbra Inc (PEN), noting its current valuation score of 7.10, which ranks 176 out of 204 in its industry. The company's current P/E ratio is 72.21, significantly below its recent high but above its recent low. The article indicates ", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-pen/company-valuation", "source_name": "TradingKey", "published_at": "2026-06-18T05:17:37", "published_display": "18 Jun 2026 05:17", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Penumbra (PEN) Proxy filing Summary", "summary": "", "url": "https://news.google.com/rss/articles/CBMickFVX3lxTE8yOHJYZDgxeXAxYWFpNGZPX0JPT1d1UjV4RW1JSXAyR3k5Tnc1NUZLMVVLdXd1QTV2MXpJam1iQWtmYjBfWXlwZFNhRFdlUnlfbnhaRnBvZmIyT180NDBmaExIYWROQUd5aHZxVWM3cHZmQQ?oc=5", "source_name": "Quartr", "published_at": "2026-06-17T23:01:11+00:00", "published_display": "17 Jun 2026 23:01", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Penumbra\u2019s Thunderbolt approval poised\u00a0to accelerate neuro thrombectomy innovation", "summary": "", "url": "https://finance.yahoo.com/m/cf411648-b137-379e-b044-28ad560b14df/penumbra%E2%80%99s-thunderbolt.html", "source_name": "Medical Device Network", "published_at": "2026-06-16T16:27:49+00:00", "published_display": "16 Jun 2026 16:27", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why Is Penumbra (PEN) Down 1.2% Since Last Earnings Report?", "summary": "", "url": "https://news.google.com/rss/articles/CBMikgFBVV95cUxQSWFfejhmNk9xYTBZZHhMVGpROUlUUzZsTTI1N3lkUG0wa2dNbjNHZE5JX1hSa2FiTUJVZjZQeWJQd3hUUHdicS1lb05pUEpscElQNVRGQXNaVE50Y1ZjUFRxRlk3Tm0ySkVwSGJ5TEpmYXVTSk4yUk1qT0YtbDJXRU9vdkZOYXRnOGJLX29vbUk5Zw?oc=5", "source_name": "Market source", "published_at": "2026-06-05T07:00:00+00:00", "published_display": "05 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Assessing Penumbra (PEN) Valuation As Growth Expectations Meet A Premium P/E Multiple", "summary": "", "url": "https://news.google.com/rss/articles/CBMipwFBVV95cUxNTDVEZWw4a3Vqb094eVBfcTBrOG1jcTZmbmVma0N4TEJibi10N3d0MWNYM1NhVVBfbVZveDVBM20wTy1mT1BhVW11Z2JxRjBUUmJDYWRQRFpwOTNPNFQ4NGpjbXhEYXNIM3Zpd1FPcXQ1aDNjWVVfWXhrMWc4WEs3NDYxanhUNU96eEcyY291anhrYUtORUYzbHBaWWdvOXl2RWZXcE93aw?oc=5", "source_name": "Market source", "published_at": "2026-05-07T07:00:00+00:00", "published_display": "07 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Penumbra (NYSE: PEN) shareholders approve Merger Proposal; closing conditions remain", "summary": "", "url": "https://news.google.com/rss/articles/CBMisgFBVV95cUxNNkI2c0pmckFQaVF1MUhKVUhRTG5PaF9vMDY0c0VEZ0FTX1BmQmNid1U2dnRvcnViUGZTSmVEakRBeUVlNmFxZEFjNkhWT2JxcXpnRkZyOHpuUHVYak1GdVhJVXQ0Q0QtNUtzWk53M2VIMEVseV9uQ1MwamloWUY5MGxFbUVrTnhoTG9Za2pwbEtkUWZRRzJfN1JKWVNtSHEtN1ZVQ05kb3RVUzJaclMtRkxB?oc=5", "source_name": "Stock Titan", "published_at": "2026-05-07T07:00:00+00:00", "published_display": "07 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Penumbra posts $32.6M profit as Boston Scientific deal halts outlook", "summary": "", "url": "https://news.google.com/rss/articles/CBMipgFBVV95cUxQQllMRGoyOGRaYW9rbUF5d0FZSDV4eU1DNk5kbWwxcDVFekdRMHZqV1pDVFBQTTl1R1Y0SUJyU2RKbDBGVnZEVFJvYk1EVlRjVWpMd2p6QzdiVEJDWk5LblB4eEQ0TVdVaW5wUjctMnlIN1Y0aTVzdG1KekxCZ3dnbHEzNGVPRGcyOTRDcXBjdkZEV1psa2I2OENLd2lvamNmM3lJMTNR?oc=5", "source_name": "Stock Titan", "published_at": "2026-05-06T07:00:00+00:00", "published_display": "06 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Penumbra (NYSE: PEN) outlines 2026 meeting and $14.5B Boston Scientific sale", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxQcWxtM0hQdl9xXzBCWDJoWnZXYUtuNG92ZjM2cDZHS2NHOE1LUncxU1FiS2praXVrMHVGZFNqRG0tdWlKSjFzcDJxX1phY1pNTGlsRDBSWm5NSFdIMVdvMlJYNjgtdS1jSFlmcEhlYkx3X0dzbVVKbC1ydXp5d2lySTNzNkRrZEx4N0ppSHFLbnhmTkdmUHUxNXRfQUtuRUpMWUFLaGRwdU9QaFJr?oc=5", "source_name": "Stock Titan", "published_at": "2026-04-29T07:00:00+00:00", "published_display": "29 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Penumbra Sale To Boston Scientific Puts Focus On Deal Terms And Future", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-03-04T08:00:00+00:00", "published_display": "04 Mar 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why is Boston Scientific Acquiring Penumbra", "summary": "", "url": "https://news.google.com/rss/articles/CBMihAFBVV95cUxNYW1NbVZkcGZsQ0g1VV9jakNiN1lxMnNMdWNPLXpjZm9VTDFwdWN4cnNPanh5NmFvQnNxQmdWbFRSRXotcXRYc3VmSEYwcWtLM0NZdjJsNDUyYWRzWVY0MzRNemhsMzNpOWF3blBWZGFUcmc0X1drWEZnQnEyT3NwcldJaEk?oc=5", "source_name": "Kavout | AI", "published_at": "2026-02-27T21:38:00+00:00", "published_display": "27 Feb 2026 21:38", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Penumbra, Inc. Reports Fourth Quarter and Full Year 2025 Financial Results", "summary": "", "url": "https://news.google.com/rss/articles/CBMixwFBVV95cUxQLXl2Q1p2cGlfd1YtQUlva2hlZ1J1eWs4V1JkLXVoSG95clZHdGJDOFBzU00xRzhHLXpuS2R4Z2RLci10UHhrbXNXcmRmdzA4WFFHWE95QUFqeTBHTGJVMXhDUVFjNVNwZzM3Qk8zUkJoaVBOcnNCaENBOWRfTm1vM0o3c0tmQ2QxRWx2OXBfTUlzNmpaMTg0bkpaYWU0Mm9tY19WQk5wVFlVMDFTZ0s2WWxxT1RqRG1Ib191T3V0c25zN1QteVhJ?oc=5", "source_name": "PR Newswire", "published_at": "2026-02-25T08:00:00+00:00", "published_display": "25 Feb 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Penumbra Inc SEC 10-K Report", "summary": "", "url": "https://news.google.com/rss/articles/CBMilAFBVV95cUxPeVg5SkpYUnRWZEk2QjRwaFowc2lJZHNlYUVHakFkeEtkRTlSRnhOSk5LeVl2RE9tX20tTTRjS0VXbGgxd3dnbnktcDc1M1dxWXdtU1JJZkFybXJuN1lFMUw2VXVlVWNfd0tCcXoxUFpKT2lIT0xhbk9jNlNZakFVVTdOb00xcTFpMFZBMVpaNmZicy0z?oc=5", "source_name": "TradingView", "published_at": "2026-02-25T08:00:00+00:00", "published_display": "25 Feb 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Penumbra (PEN) Climbs to All-Time High on $14.5-Billion Merger", "summary": "", "url": "https://news.google.com/rss/articles/CBMigAFBVV95cUxPdkhyYXBXZ05DQ2hQRUcwejdKS1pUS1ptSWY4aVc5WnpXNk5JRUc1aTF3VXdTRmI1RHpLQ0JPZmVHS3lUN2pZX19rMVozS1E0WkgtbXdDT2tWb1RsQ2VCSmdKbl85eTVvRUs2czNsY0JOckREN2FQN0UtSXlBMlFRZw?oc=5", "source_name": "Market source", "published_at": "2026-01-16T08:00:00+00:00", "published_display": "16 Jan 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Boston Scientific announces agreement to acquire Penumbra", "summary": "", "url": "https://news.google.com/rss/articles/CBMiiAFBVV95cUxNUWg3ck5YN2pOYkpFcjZMWjc4VXFTek9od2RFTThIV3UtZHpNTllCTkYzckxWQWVhMzVBQ2xXSXRyVjZRZnlaLUtyZjV4MTlCRzhfRVI2V1R2LWx2NXJ1aVQyLUhId2dpR3AtaldlY3FoRXk2eko4djVsOGV6VGIwLW9ndW9uX2ky?oc=5", "source_name": "Venous News", "published_at": "2026-01-15T08:00:00+00:00", "published_display": "15 Jan 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Boston Scientific set to re-enter neurovascular market with Penumbra acquisition", "summary": "", "url": "https://news.google.com/rss/articles/CBMitwFBVV95cUxPcHBJTzVtWGkxME5mWkVhN2RwYzR5b25vdmZuTnRIaUtNR0daT0tKZmtYSmRJRmZTaXlldjdUU3RxMmpEeWF2UVMwLUJnejgtLXltVUxacGJCRHlPQXlaNzRtR3lQVmpDbGpHbXk2MXdKanRycXdqN1U4cGtxY1R5U00wMUdxVC1FYl9YaGhEZmdETVlfTU5Ickt0eWxoZDFhS2drUXlmdUlPbmVZZVcyUm4wcDVvNms?oc=5", "source_name": "NeuroNews International", "published_at": "2026-01-15T08:00:00+00:00", "published_display": "15 Jan 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Boston Scientific Acquiring Penumbra Was The Logical Next Step (NYSE:BSX)", "summary": "", "url": "https://news.google.com/rss/articles/CBMioAFBVV95cUxNNVNSUFZtVTRrNXBSWGEyNTd6ZWxQUlZVdVRkM05iUzdLQVl0YzRvTmRlWGZ2SlM5d1Q5aXVvaHlrYzVWTWZ1MzBoSWtTR044OFlYMVhnN3NvVTBMWHpWWjk4UDBDRFplbG9FV2x4eHp5d0h0Z1FlejZLaG1VZUJHOXk1SVNuM3BHWXRQZ1FjQTI0VWh2OV9JRlRuN1RMNW1K?oc=5", "source_name": "Seeking Alpha", "published_at": "2026-01-15T08:00:00+00:00", "published_display": "15 Jan 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why Penumbra (PEN) Stock Is Trading Up Today", "summary": "", "url": "https://news.google.com/rss/articles/CBMiggFBVV95cUxPaENxeWxWWnFEN2taQ3VaSlR1TV9laHRJaWdoM1ZXSXN6cUFPQ29JUjdFZzg1TWdfcmtoSi16Yy1UbVNGUlVvODVWNGFRMmRvNkE1VERidjJrbnFtZXhWSWRUZ19UYnRaZ19RYlRpbVJZTW1LdVRUTHFCSnpXZGtvMC1R?oc=5", "source_name": "Market source", "published_at": "2026-01-15T08:00:00+00:00", "published_display": "15 Jan 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Do Penumbra's (NYSE:PEN) Earnings Warrant Your Attention?", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-01-11T08:00:00+00:00", "published_display": "11 Jan 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Penumbra, Inc. Reports Third Quarter 2025 Financial Results", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPMzRSZDhQa1Y5RllQdEg2SVdLdWN2ODYxTUI1aVpEUlhOSU9LR1FmWnQzUk1NeEc1M1MxeExTZ1dCTmxrYkdiWHFZOFBRejVtd2RTcHA3VjRralJlbnNNTzFtWERIMTNkMmlFUXhTSV9BdFYySDd3a09WemZtRklTcFdiQkRjYlBvZjdqSy1WUER4SmV5ck02V1VBaGJDNmxiemo0VFI1UksyLTZFdUVkWUFTbw?oc=5", "source_name": "PR Newswire", "published_at": "2025-11-05T08:00:00+00:00", "published_display": "05 Nov 2025 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}], "industry": [{"title": "Reflecting On Medical Devices & Supplies - Specialty Stocks\u2019 Q1 Earnings: Integer Holdings (NYSE:ITGR)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqgFBVV95cUxNUFd1SUpRcWlCdEFjU1YzNTZkdjBfRkwyY2lBYjh1ZXZlZTlyVlpWSWx1bExvckFrNHNhUEdVTGNFWUxaMkVDZUV2c2hPS1h2YVhNSHNsVzFYNUFrNHBnRVM1STRsa2Zmb0VXeEQ4UFRGNDBOWXZfWVU5VFUyQ3JZZm9KamZMWXVDSEtNMWwyVktpaEZfRjVNU1BYaWJ3NnpNUmRyMEpsSzBXdw?oc=5", "source_name": "Market source", "published_at": "2026-07-14T18:07:11+00:00", "published_display": "14 Jul 2026 18:07", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Medical Devices & Supplies - Cardiology, Neurology, Vascular Stocks Q1 Earnings: ICU Medical (NASDAQ:ICUI) Firing on All Cylinders", "summary": "", "url": "https://news.google.com/rss/articles/CBMikAJBVV95cUxQLWl0NWl5MFJhUXFSN0pzSW1sVzJVb21XVml0X0doQnd5eDVUQmVqeFZWSmNmdlZaV2pfbFk3UEl3RXlqZ05pckozR0dnNHNEUlpTa2FPYWc1Z3Q0Y2tXYTljZUlQRkVZNzY2Sl9yRksyUDJkNVQzSTBuLW9uMnI5bzBfTTJGdDUzd25DN3dDSmhwWnpGVXZRVVM2Uy1zMnp4STZ1RGdZZkRpZ21Pb2xtWjRSTk1kc2JrT28wTG81NDV1M2tWaVdrOXBQdVZSTExiTVEzMXpqRnJWWi0xcEdMYVFILXZXbXZVZl9GRm12aTl5OGk4X1dSVjVyU2FIVFpubk1YNm5fQll0MVZqRTZpTA?oc=5", "source_name": "StockStory", "published_at": "2026-06-15T07:00:00+00:00", "published_display": "15 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Q1 Earnings Review: Medical Devices & Supplies - Diversified Stocks Led by Baxter (NYSE:BAX)", "summary": "", "url": "https://news.google.com/rss/articles/CBMipgFBVV95cUxNYjhBT3BjMWFVU1FFUUFub0d6QUVEUTdwWFVMRG5fN2dHSnIxTXQwMWU1aElKaEV1a2dYLTFHMlBzMVFTZEtaX0xRRDFhZDl1WFdDYWF2RDZxOG9SRUtycmZacTRzM2FaaEU3OS1GZ2taLWtSMjZ4enhVNHRvdzJsanp4cEhNcGI1dllTOUplWUUtNjRlRm85MlFEVWxSYUV2d243QVd3?oc=5", "source_name": "Market source", "published_at": "2026-05-21T07:00:00+00:00", "published_display": "21 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Medical Devices & Supplies - Specialty Q4 Earnings: Globus Medical (NYSE:GMED) is the Best in the Biz", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqgFBVV95cUxNcDFMNmtOVk5PVFM1YzMyVWhyS3dwY0dMVE5BUng5U1JoOFRQMXNFRGxTMmlBRUV0bENRSWFXTDFZOXBQQkNZT0FOWDdISjRCcU9pRV9aNHBwUVBuZkVEV3g1dklVY19KOE9iWUNpNUtMS2NuOEcxMlQtNU8ydURybEdkNVoxZThWLTBIeVhid2NjQ0FWWTUzb2dxcmlMQThFQmZ4bldzRjcwUQ?oc=5", "source_name": "Market source", "published_at": "2026-04-27T07:00:00+00:00", "published_display": "27 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "A Look Back at Medical Devices & Supplies - Imaging, Diagnostics Stocks\u2019 Q4 Earnings: Hologic (NASDAQ:HOLX) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMipgFBVV95cUxOdkl6Ym5HSGVhZUw3TzNlNVFPSjdDQk5NMTVSRW1xVnh3RE5RNU9veVR0TDEtcVdxV3BYelI0bWxCYXgwWmhZQ3ZONUVRdlhjX0ZiMklRVDJQRXN0LXcyVWVnb0E2WTdiRERtZk1pNGpmVHhWbHl5eHJuNnBtTDVPMUluTmRsQUVqYjNlSl8zR3djclh0X2ZIc1gzTlhPanR6ZTJ6R1FB?oc=5", "source_name": "Market source", "published_at": "2026-04-07T07:00:00+00:00", "published_display": "07 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Q4 Earnings Highlights: Artivion (NYSE:AORT) Vs The Rest Of The Medical Devices & Supplies - Cardiology, Neurology, Vascular Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqAFBVV95cUxPaTgxS3dlMlZ5dDZ3dFlGdG9yRWFubkVqMk9yOTN6OEtyemljTWJGYUcxb2pmd2FTNTFKMlhIVGxrdlJsOG5iY1VQaXE4ZmYycTVpRkE0aEJ3QlB5bC10ZXN2dTFYNy0wRWdrNURVUlo5dEMzQklxQ0kwQTRkOXE0UDdTMkRGRWxoQ1ZQeG4tOXNONlR2SkxfZW5ST1B6N3BBeFZZQ3N1UFE?oc=5", "source_name": "Market source", "published_at": "2026-04-02T07:00:00+00:00", "published_display": "02 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Q4 Earnings Highlights: CooperCompanies (NASDAQ:COO) Vs The Rest Of The Medical Devices & Supplies - Diversified Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMitAFBVV95cUxOellVLTAtRXF1dTFacmVLUmptUVpDSkxGX0MtY2hCY2l3ajU4M25SMG95OHdlc1RHN1dmaHZZMF9uQ0o3R1FBa0NzQUtZMjIzMjU1bmttbGZsZUplQkd5Vmd2NEJoQ0NnbVhmVXppdWhiQkdpcGpQVFJVSHRBXy1pbnFJbXI0R2w3MmlvMEdCY2dGYVE4cWY2MENmeEp1ME9mZEFqSDVtdThTMk9kbUhIdXMtR0k?oc=5", "source_name": "Market source", "published_at": "2026-03-25T07:00:00+00:00", "published_display": "25 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Unpacking Q4 Earnings: Integer Holdings (NYSE:ITGR) In The Context Of Other Medical Devices & Supplies - Specialty Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMijAFBVV95cUxQZXhDWktWZlhhSHlxNVZrNWllaDhhWlNXZmhKYlQ4ODRJMHozNTR2TVVKSWVrQV94bzNNU0hfVW5qODRlWW01anFmTG5SYmZoUlJpU09UbkpSemxVbHRGb1F1MGVvZFdqSEVBcUZ5Ti1ZVHlzY3pZYTdCS21RcDJPTnppdWRKVlZjd2ZUeA?oc=5", "source_name": "Market source", "published_at": "2026-03-17T07:00:00+00:00", "published_display": "17 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Q4 Earnings Highs And Lows: Abbott Laboratories (NYSE:ABT) Vs The Rest Of The Medical Devices & Supplies - Diversified Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMigAFBVV95cUxPeVpVN2I3X3lJNXd3TXJmRWV4X0RvRDdYR3l5a1k1SjMxUlhsWHdrUUNuZ1JIaUg4czdhZlA2VDVIallROFFuNmZXcnNzS1d3Vm0wS0tLMmlFVWdkUThsRDZYdTdZV3k3WkRjaUZSMUQ3dkRKYm5ZOVBjMVVBdTRjYQ?oc=5", "source_name": "Market source", "published_at": "2026-03-12T07:00:00+00:00", "published_display": "12 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Unpacking Q4 Earnings: Enovis (NYSE:ENOV) In The Context Of Other Medical Devices & Supplies - Specialty Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMihgFBVV95cUxNMzBPcXU1cnZKekZnaGlNVk05ZWFTWThNOS0tTlpvQjdaLVZIWlVXUk50NnVoQ0pPWWJpZUpWcVJyVDJMd2RJREVDbEEzTlU5UGhBbWtxWVEyVkdaMTVuNXZpaWFMNTZUQ2d0OW9Rc29kalJRY21naWlHZDBLS3RuZV9wdTdIUQ?oc=5", "source_name": "Market source", "published_at": "2026-03-10T07:00:00+00:00", "published_display": "10 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}], "sector": []}, "total_fetched": 107, "total_relevant": 61, "sentiment_summary": {"positive": 12, "negative": 0, "neutral": 49, "score": 55, "total": 61, "label": "Balanced news tone", "tone": "neutral"}, "classifier": {"primary_event": "general", "primary_label": "Market update", "confidence": 75, "events": [{"event": "general", "label": "Market update", "weight": 14.1, "count": 25}, {"event": "earnings", "label": "Earnings", "weight": 10.17, "count": 21}, {"event": "deals", "label": "Deals and strategy", "weight": 4.9, "count": 7}, {"event": "analyst", "label": "Analyst action", "weight": 2.0, "count": 3}, {"event": "regulatory", "label": "Regulatory and legal", "weight": 1.65, "count": 3}, {"event": "guidance", "label": "Guidance", "weight": 1.1, "count": 2}], "positive_events": 12, "negative_events": 0}, "market_context": {"has_market_context": true, "latest_close": 318.1, "latest_week": "2026-07-10", "one_week_move": -0.1, "four_week_move": -0.2, "twelve_week_move": -4.2, "trend_signal": "0", "trend_label": "Trend inactive", "trend_tone": "negative", "market_dynamics": -1.471525, "market_dynamics_buy_signal": false, "relative_strength": -4.837045, "fair_value_gap": 23.4, "fair_value_label": "Near fair-value range", "fair_value_tone": "neutral", "expectation_direction": "undecided", "expectation_probability": 48.9962, "reaction_label": "Price digesting", "reaction_tone": "neutral", "market_sentence": "-0.1% over one week, -0.2% over four weeks, trend inactive, and near fair-value range."}, "interpretation": {"label": "Balanced read", "tone": "neutral", "classification": "balanced", "summary": "News tone and price action are not far from neutral.", "confidence": 52, "badges": [], "opportunities": [], "risks": [], "event_label": "Market update", "sentiment_word": "balanced"}, "charts": {"sources": [{"label": "Market source", "count": 13}, {"label": "TradingView", "count": 9}, {"label": "simplywall.st", "count": 4}, {"label": "Stock Titan", "count": 4}, {"label": "Morningstar", "count": 3}, {"label": "Stock Traders Daily", "count": 2}, {"label": "MedTech Dive", "count": 2}, {"label": "Investing.com", "count": 2}], "tiers": [{"label": "Direct company coverage", "count": 51}, {"label": "Industry context", "count": 10}, {"label": "Sector context", "count": 0}], "events": [{"label": "Market update", "count": 25}, {"label": "Earnings", "count": 21}, {"label": "Deals and strategy", "count": 7}, {"label": "Analyst action", "count": 3}, {"label": "Regulatory and legal", "count": 3}, {"label": "Guidance", "count": 2}]}, "insights": [{"label": "Weighted tone", "value": "55/100", "tone": "neutral", "text": "Balanced news tone"}, {"label": "Market reaction", "value": "Balanced read", "tone": "neutral", "text": "News tone and price action are not far from neutral."}, {"label": "Primary event", "value": "Market update", "tone": "neutral", "text": "75/100 classification confidence."}, {"label": "Company focus", "value": "51", "tone": "positive", "text": "directly relevant articles"}, {"label": "Source quality", "value": "5", "tone": "positive", "text": "high-authority source matches"}, {"label": "Trend context", "value": "Trend inactive", "tone": "negative", "text": "-0.1% over one week, -0.2% over four weeks, trend inactive, and near fair-value range."}, {"label": "Latest direct headline", "value": "Neutral", "tone": "neutral", "text": "Analyst Report: Penumbra, Inc."}], "updated_at": "2026-07-18T08:47:09.058281+00:00", "disclaimer": "Educational market research only. Not financial, investment, trading, tax, or legal advice."}